Endpoints News
Mineralys tightens hold on hypertension drug Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
3 June, 2026
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
top stories
1. Regeneron doubles down on CytomX after other pharmas walked away
2. Mineralys makes money moves before looming hypertension approval
3. Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
4. Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
5. What’s next for VEGF? ASCO offered clues, but answers will have to wait
6. Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech
7. FDA details flexibilities for new cell and gene therapies to leverage past data
8. Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
9. Lilly gives hospitals deadline to comply with 340B claims data policy
more stories
• 
Karen Weintraub
.

It's not too late to join our ASCO event, where reporter Lei Lei Wu is talking with Pfizer's chief oncology officer and KRAS pioneers. We're live from 11 a.m. to 12:30 p.m. ET.
.
Karen Weintraub
Deputy Editor, Endpoints News
Sean McCarthy, CytomX CEO
1
by Kyle LaHucik

Af­ter los­ing a cou­ple of phar­ma al­liances in re­cent quar­ters, Cy­tomX Ther­a­peu­tics is get­ting a ma­jor lift from a key col­lab­o­ra­tor.

Re­gen­eron is dou­bling down...

Read full story
Jon Congleton, Mineralys Therapeutics CEO
2
by Kyle LaHucik

Min­eralys Ther­a­peu­tics first drew at­ten­tion in 2021 with a bold bet on a new type of hy­per­ten­sion drug called lorun­dro­stat. It came with a tiny...

Read full story
3
by Ryan Cross

Last month, As­cid­i­an Ther­a­peu­ticspre­sent­ed the first da­ta sug­gest­ing a new way to fix bro­ken genes may be safe in peo­ple. Now Eli Lil­ly has...

Read full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
4
by Andrew Dunn

The Bay Area start­up NewLim­it has closed one of biotech's largest pri­vate fi­nanc­ings of 2026 and ex­pects to start hu­man test­ing next year for its...

Read full story
5
by Max Gelman

CHICA­GO — Not long ago, there were hopes that a new class of can­cer drugs would re­peat the suc­cess of Keytru­da. In­stead, it seems more...

Read full story
6